Delivery Order SPE2DB25D3109-SPE2DB25FPKZW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $25,189.80 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) valued at $3,352.74. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $58,587.97 and utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $74,205.29. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made competitively without set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $11,859.53 to AmerisourceBergen Drug Corp on July 14, 2025, for RINVOQ ER 15 mg tablets (quantity: 30 units). This competitive award, using firm fixed price terms with no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of RINVOQ ER 15 MG tablets in a quantity of 30 units. The contract is valued at $6,223.32 and represents a firm fixed price delivery order with an ultimate completion date of April 23, 2025. This award was made without a set-aside designation, indicating competitive procurement. The vendor will perform delivery from its corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $40,566.55 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB25FPKZWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $11,191.56 with a firm fixed price structure and carries an ultimate completion date of August 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.999 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, has established itself as a primary supplier to the Defense Logistics Agency's medical supply chain. The company delivers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs and related federal health systems. RINVOQ (upadacitinib), the specific medication in this delivery order, is used for treating rheumatoid arthritis and other inflammatory conditions. This award demonstrates AmerisourceBergen's continued capability to fulfill federal procurement requirements through competitive contracting, consistent with its portfolio of similarly structured delivery orders with fixed pricing across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 8/21/25 |